期刊文献+

盐酸布桂嗪联合盐酸异丙嗪辅助治疗顽固性癌痛的临床疗效观察 被引量:5

Bucinnazine hydrochloride combined with promethazine hydrochloride clinical observation on the treatment of intractable cancer pain patients
下载PDF
导出
摘要 目的观察晚期肿瘤患者出现顽固性癌痛时,应用盐酸布桂嗪注射液联合盐酸异丙嗪注射液镇痛的疗效及安全性。方法采用回顾性分析方法,将72例顽固性癌痛患者,按照疾病的病理类型分为两组,联合组(L组)给予盐酸布桂嗪皮下注射联合盐酸异丙嗪肌内注射,对照组(D组)给予盐酸布桂嗪皮下注射。将两组患者药物平均起效时间,镇痛平均维持时间,镇痛疗效,不良反应进行分析比较。结果镇痛平均起效时间:联合组与对照组相近,两组比较差异无统计学意义(P>0.05);镇痛平均维持时间:联合组镇痛平均维持时间显著延长,两组比较差异有统计学意义(P<0.05);镇痛疗效:联合组镇痛疗效优于对照组,两组比较差异有统计学意义(P<0.05);不良反应:联合组主要为轻度嗜睡(55.5%),对照组主要为恶心呕吐(47.2%)。结论在实际临床使用中,缓解晚期癌症患者顽固性疼痛,改善患者生活质量,联合组镇痛疗效好,维持时间长,不良反应程度轻,具有临床使用优势。 Objective To observe the analgesic efficacy and safety of using Bucinnazine Hydrochloride injection combined with Promethazine Hydrochloride injection among patients with advanced cancer when they have intractable pain. Methods Retrospective analytic method was used and 72 cases of patients with refractory cancer pain treated in hospital were assigned into two groups according to the pathological types of disease. The combined group( group L) was given subcutaneous injection of bucinnazine hydrochloride combined with intramuscular injection of promethazine hydrochloride while the control group( group D) was given subcutaneous injection of bucinnazine hydrochloride. Time of analgesic onset,analgesic duration,analgesic effect and adverse reactions among the two groups of patients were compared. Results There was no statistically significant difference in the time of analgesic onset( P〈0. 05); the time of analgesic duration was significantly longer in group L than in group D( P〈0. 05) and the analgesic effect was significantly better in group L than in group D( P〈0. 05). Main adverse reactions was mild hypersomnia( 55. 5%) in group L and sick and vomiting( 47. 2%) in group D. Conclusion In clinic,the combined use of bucinnazine hydrochloride injection with promethazine hydrochloride injection can ease the advanced cancer patients with intractable pain,improve the quality of life of the patients,which has the advantages of better analgesic results,longer analgesic duration,and fewer adverse reactions.
作者 姚春根
出处 《安徽医药》 CAS 2016年第7期1398-1400,共3页 Anhui Medical and Pharmaceutical Journal
关键词 疼痛 顽固性 异丙嗪 镇痛药 阿片类 Pain Intractable Promethazine Analgesics Opioid
  • 相关文献

参考文献10

二级参考文献67

  • 1刘华,王蔚,郑垂志,邢雪花.癌症三阶梯止痛563例分析[J].中国肿瘤临床,2004,31(23):1346-1348. 被引量:79
  • 2刘生智,贺锋,薛利军.蛛网膜下腔持续泵注吗啡治疗晚期癌痛[J].实用疼痛学杂志,2005,1(3):143-144. 被引量:3
  • 3Goudas LC, Bloch R, Gialeli-Goudas M, et al. The epidemiology of cancer pain [ J ] . Cancer Invest, 2005, 23:182-190. 被引量:1
  • 4Svendsen KB, Andersen S, Arnason S, et al. Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms [ J ] . Eur J Pain, 2005, 9:195-206. 被引量:1
  • 5Dhingra L, Lam K, Homel P, et al. Pain in underserved community-dwelling Chinese American cancer patients:demogtaphic and medical.correlates[J].Oncologisl, 2011, 16:523-533. 被引量:1
  • 6Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes [ J ] . Ann Onc, 2009, 20:1420-1433. 被引量:1
  • 7Thapa D, Rastogi V, Ahuja V. Cander pain management-current status [ J ] . J Anaesthesiol Clin Pharmacol, 2011, 27:162-165. 被引量:1
  • 8Greene ER, Huang S, Serhan CN, et al. Regulation of inflammation in cancer by eicosanoids [ J ] . Prostaglandins Other Lipid Medial, 2011, 96:27-36. 被引量:1
  • 9Lipton A, Campbell-Baird C, Witters L, et al. Phase ll trim of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer [ J] . J Clin Gastroenterol, 2010, 44:286-288. 被引量:1
  • 10Koch A, Bergman B, Holmberg E, et al. Effect of celeccoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group [ J ] . Eur J Cancer, 2011, 47:1546-1555. 被引量:1

共引文献64

同被引文献71

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部